Generics in Japan

Date: October 27, 2017
Pages: 34
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GDBE6BEE215EN
Leaflet:

Download PDF Leaflet

Generics in Japan
Generics in Japan

SUMMARY

Generics in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS

Essential resource for top-line data and analysis covering the Japan generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

KEY HIGHLIGHTS

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The market value is evaluated at ex-factory prices.
Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
Please note that any volumes of '1' (one) or 100% are due to rounding as MarketLine does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
All currency conversions were calculated at constant average annual 2016 exchange rates.
The Japanese generics market had total revenues of $45,850.0m in 2016, representing a compound annual growth rate (CAGR) of 10.5% between 2012 and 2016.
Market consumption volume increased with a CAGR of 10.7% between 2012 and 2016, to reach a total of 65.5% of total pharma volume in 2016.
Cost reduction is a priority in Japan and the government is widely accepting generics as an alternative for branded medicine.

SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Japan
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Japan
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Japan generics market with five year forecasts by both value and volume
REASONS TO BUY
  • What was the size of the Japan generics market by value in 2016?
  • What will be the size of the Japan generics market in 2021?
  • What factors are affecting the strength of competition in the Japan generics market?
  • How has the market performed over the last five years?
  • How large is Japan’s generics market in relation to its regional counterparts?


NOTE: Out of security concerns MarketLine requires using corporate email address.
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Sawai Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
Daiichi Sankyo Co., Ltd.
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Japan generics market value: $ billion, 2012-16
Table 2: Japan generics market volume: % of total pharma volume, 2012-16
Table 3: Japan generics market geography segmentation: $ billion, 2016
Table 4: Japan generics market value forecast: $ billion, 2016-21
Table 5: Japan generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Sawai Pharmaceutical Co., Ltd.: key facts
Table 7: Sawai Pharmaceutical Co., Ltd.: key financials ($)
Table 8: Sawai Pharmaceutical Co., Ltd.: key financials (¥)
Table 9: Sawai Pharmaceutical Co., Ltd.: key financial ratios
Table 10: Teva Pharmaceutical Industries Limited: key facts
Table 11: Teva Pharmaceutical Industries Limited: key financials ($)
Table 12: Teva Pharmaceutical Industries Limited: key financial ratios
Table 13: Daiichi Sankyo Co., Ltd.: key facts
Table 14: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 15: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 16: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 17: Japan size of population (million), 2012-16
Table 18: Japan gdp (constant 2005 prices, $ billion), 2012-16
Table 19: Japan gdp (current prices, $ billion), 2012-16
Table 20: Japan inflation, 2012-16
Table 21: Japan consumer price index (absolute), 2012-16
Table 22: Japan exchange rate, 2012-16

LIST OF FIGURES

Figure 1: Japan generics market value: $ billion, 2012-16
Figure 2: Japan generics market volume: % of total pharma volume, 2012-16
Figure 3: Japan generics market geography segmentation: % share, by value, 2016
Figure 4: Japan generics market value forecast: $ billion, 2016-21
Figure 5: Japan generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Japan, 2016
Figure 7: Drivers of buyer power in the generics market in Japan, 2016
Figure 8: Drivers of supplier power in the generics market in Japan, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Japan, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Japan, 2016
Figure 12: Sawai Pharmaceutical Co., Ltd.: revenues & profitability
Figure 13: Sawai Pharmaceutical Co., Ltd.: assets & liabilities
Figure 14: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 15: Teva Pharmaceutical Industries Limited: assets & liabilities
Figure 16: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 17: Daiichi Sankyo Co., Ltd.: assets & liabilities

COMPANIES MENTIONED

Sawai Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
Daiichi Sankyo Co., Ltd.
Skip to top


Japanese Generic Market Forecast to 2013 US$ 800.00 Mar, 2011 · 45 pages

Ask Your Question

Generics in Japan
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: